Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.39 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.39 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13754943 | 0.82 | NR3C2 (0.50) | NR3C2HTTKDM5AKDM5BKDM4E | |
| SCHEMBL7089255 | 0.80 | NOS2 (0.36) | NR3C2HTTKDM5AKDM5BKDM4E | |
| SCHEMBL16502197 | 0.79 | NR3C2 (0.51) | NR3C2MAOAMAOBKDM5AKDM5B | |
| SCHEMBL7092679 | 0.77 | SKP2 (0.39) | HTTKDM4E | |
| SCHEMBL21645886 | 0.76 | CDK1 (0.40) | NR3C2KDM4E | |
| SCHEMBL15724953 | 0.76 | CDK5 (0.32) | — | |
| SCHEMBL764017 | 0.76 | RECQL (0.52) | MAOA | |
| SCHEMBL29026954 | 0.76 | LOXL2 (0.52) | ROCK1 | |
| SCHEMBL29935916 | 0.76 | RECQL (0.52) | MAOA | |
| SCHEMBL6642166 | 0.76 | NOS3 (0.52) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12065409-B2 | Analogs of 2-pralidoxime as antidotes against organophosphorus nerve agents | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2024-08-20 | — | — | US | disclosed |
| US-20210317084-A1 | Analogs of 2-Pralidoxime as Antidotes Against Organophosphorus Nerve Agents | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317084-A1 | Analogs of 2-Pralidoxime as Antidotes Against Organophosphorus Nerve Agents | ACHE, DDT, BCHE | NR3C2 4535/4885HTT 4122/4885MAOA 351/4885 |
| US-12065409-B2 | Analogs of 2-pralidoxime as antidotes against organophosphorus nerve agents | ACHE, DDT, BCHE | NR3C2 4535/4885HTT 4122/4885MAOA 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.